Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Any mice that lost more than 20% of the initial weight during treatment, or tumor diameter exceeded 15 mm, were immediately eliminated from this sample and were not counted in the statistical analysis
Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer
MTSL caused peak broadening near the labeled residues, allowing us to identify which region of the FOXO4 FHD was close to the p53 TAD
1e and Extended Data Fig
US$ 26.49
US$ 25.36
US$ 24.16
US$ 25.31
US$ 27.65
US$ 23.54
US$ 22.25
US$ 20.67
US$ 21.54
